Patents

Search tools Text Classification Chemistry Measure Numbers Full documents Title Abstract Claims All Any Exact Not Add AND condition These CPCs and their children These exact CPCs Add AND condition
Exact Exact Batch Similar Substructure Substructure (SMARTS) Full documents Claims only Add AND condition Add AND condition
Application Numbers Publication Numbers Either Add AND condition

Фармацевтични състави от адсорбати на аморфно лекарствено средство

Classifications

A61K47/50 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
View 30 more classifications

Landscapes

Health & Medical Sciences Chemical & Material Sciences
Show more

BG108489A

Bulgaria

Download PDF Find Prior Art Similar
Other languages
Bulgarian
English
Inventor
Walter C. Babcock
Dwayne T. Friesen
Ravi M. Shanker
Daniel T. Smithey
Ralph Tadday
Worldwide applications
2002 CZ CN NZ EE BR TN EA IL AT EP JP MX KR HU EP OA PL DE SK WO CA KR AU US 2003 ZA IS CR NO EC MA BG 2006 US 2008 US
Application BG108489A events
First worldwide family litigation filed
2003-12-22
Application filed by Pfizer Products Inc.
2004-07-30
Publication of BG108489A
Info
Patent citations (62)
Cited by (55)
Similar documents
Priority and Related Applications
External links
Espacenet
Global Dossier
Discuss

Patent Citations (62)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
CA1146866A * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
FR2525108B1 * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS5942313A * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
EP0129893B1 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
US4581232A * 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
IE63321B1 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4716033A * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4711774A 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
US4717565A * 1986-03-27 1988-01-05 Warner-Lambert Company Process for the preparation of medicament adsorbates
US5015479A * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4835186A * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
IT1216570B * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
IT1227626B * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IE60458B1 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
US5300302A * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5559158A * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5626878A * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
SI9500059A 1995-02-23 1996-08-31 Lek Tovarna Farmacevtskih Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba
JPH11503454A 1995-04-14 1999-03-26 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 成長ホルモン放出因子の類似体
WO1996039126A2 * 1995-06-06 1996-12-12 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
DE19532061A1 * 1995-08-31 1997-03-06 Bayer Ag N-Sulfonyliminodithioverbindungen
DE19610932A1 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627419A1 1996-07-08 1998-01-15 Bayer Ag Cycloalkano-pyridine
DE19627431A1 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AR008789A1 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19704243A1 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
CN1248968A 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
DE19709125A1 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
PT901786E * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AU9297798A 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19832159A1 1997-09-18 1999-03-25 Bayer Ag Substituierte Tetrahydro-naphthaline
DE19741399A1 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19741400A1 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
CA2304763A1 * 1997-09-29 1999-04-08 Pei Han A fagopyrum cymosum (trev.) meisn composition, method to prepare and analyze the same and uses thereof
DE69932920T2 1998-02-05 2007-02-08 Pfizer Products Inc., Groton Neue dihydroxyhexansäurederivate
WO1999041237A1 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
JPH11246404A 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
US20010025046A1 * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
JP4815053B2 * 1998-08-13 2011-11-16 シーマ・ラブス、インコーポレイテッド 経口投与の固形投与形態物としてのマイクロエマルション
US6376481B2 * 1998-09-02 2002-04-23 Mcneil-Ppc, Inc. Sterol esters in tableted solid dosage forms
US6140342A 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
EP1115695B1 1998-09-25 2005-06-01 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
EP1115694A1 1998-09-25 2001-07-18 Monsanto Company Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
EP1027887B1 * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
WO2000056286A1 * 1999-03-19 2000-09-28 Ranbaxy Laboratories Limited Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil
KR100342943B1 * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
UY26615A1 * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
AR027656A1 * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US7115279B2 * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6602523B1 * 2000-08-17 2003-08-05 Technology Holding, Llc. Composite material and process for increasing bioavailability and activity of a beneficial agent
US6596262B2 * 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
* Cited by examiner, † Cited by third party

Cited By (55)

Publication number Priority date Publication date Assignee Title
Family To Family Citations
KR20040083493A * 2002-02-01 2004-10-02 화이자 프로덕츠 인크. 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출형제약상 제형
EP1469832B2 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20040132771A1 * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US7838029B1 * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
JP2007501218A * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US7390503B1 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8025899B2 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005023225A1 * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
DK1532975T3 * 2003-11-18 2007-04-23 Helm Ag Fremgangsmåde til fremstilling af frit flydende pulverformige atorvastatin-adsorbater
DE502004001894D1 * 2004-02-06 2006-12-14 Helm Ag Pharmazeutische Zubereitungen mit amorphem Tibolon
MY142989A * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
JP2008511607A 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
GB2419094A * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
DE102004055229A1 * 2004-11-17 2006-05-18 Heidelberger Druckmaschinen Ag Zustandsabhängige Absicherung von Maschinen
US7700774B2 * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CA2605214C * 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8604055B2 * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006080312A1 * 2005-01-25 2006-08-03 Kowa Co., Ltd. 吸着多孔体の製造法
US9265731B2 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
EP1844078B1 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
WO2006085217A2 * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
EP1767194A1 * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
US8398576B2 * 2007-04-02 2013-03-19 University of Pittsburgh—of the Commonwealth System of Higher Education Removal of contrast agents from blood
CN101687872A * 2007-04-03 2010-03-31 雷迪博士实验室有限公司 培美曲塞的固体形式
EP1987816A1 * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009026461A2 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2072042A1 * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Active pharmaceutical ingredient on solid support, amorphous and with improved solubility
WO2009113522A1 * 2008-03-11 2009-09-17 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP5421252B2 * 2008-05-30 2014-02-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 経皮吸収製剤
CN107320485A * 2008-10-02 2017-11-07 匹兹堡大学-属高等教育联邦体系 用于治疗全身性炎症的吸附剂聚合物的施用
KR20110110097A * 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
KR101004205B1 * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2010092925A1 * 2009-02-12 2010-08-19 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
WO2010102065A1 * 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010111132A2 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
EP2238979A1 * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
SMT202000093T1 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2366378A1 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011110662A1 * 2010-03-11 2011-09-15 Danmarks Tekniske Universitet Supported biologically active compounds
WO2011148253A2 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
PT2611530T 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
US8815294B2 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2611529B1 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012040502A1 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
TWI520732B * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
US9084727B2 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
IN2014CN00827A * 2011-08-16 2015-04-03 Merck Sharp & Dohme
CN103827105B 2011-08-18 2016-08-17 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
KR101803866B1 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
EA037895B1 * 2014-02-05 2021-06-02 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
WO2016067132A1 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
WO2016204058A1 * 2015-06-15 2016-12-22 住友化学株式会社 有機ｅｌ素子の製造方法
KR20230097021A 2020-09-29 2023-06-30 선전 파마신 컴퍼니 리미티드 약학 조성물
CN113476408A * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用
* Cited by examiner, † Cited by third party, ‡ Family to family citation

Similar Documents

Publication Publication Date Title
AU2002302903B2 2007-05-17 Pharmaceutical compositions of adsorbates of amorphous drug
CA2448864C 2008-04-22 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
AU2002302903A1 2003-06-19 Pharmaceutical compositions of adsorbates of amorphous drug
JP2004534822A 2004-11-18 低溶解度および／または酸感受性の薬剤と中和された酸性ポリマーとを含む医薬組成物
CA2450957A1 2003-01-03 Pharmaceutical compositions of dispersions of drugs and neutral polymers
CA2391078A1 2002-12-22 Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AU2002302886A1 2003-01-08 Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers

Priority And Related Applications

Applications Claiming Priority (2)

Application Filing date Title
US30026001P 2001-06-22
PCT/IB2002/001792 2002-05-21 Pharmaceutical compositions of adsorbates of amorphous drug

Concepts

machine-extracted
Download Filter table
Name Image Sections Count Query match
drug title,claims,abstract,description 258 0.000
drug title,claims,abstract,description 250 0.000
adsorbate title,claims,abstract,description 82 0.000
pharmaceutical composition title,claims,abstract,description 13 0.000
substrate claims,abstract,description 114 0.000
mixture claims,abstract,description 99 0.000
polymer claims,abstract,description 59 0.000
hydroxypropyl claims,description 322 0.000
aryl group claims,description 95 0.000
solvent claims,description 75 0.000
substituent group claims,description 67 0.000
cholesterol ester transfer protein inhibitor claims,description 58 0.000
method claims,description 57 0.000
increasing effect claims,description 25 0.000
methoxycarbonylamino group claims,description 24 0.000
cholesteryl ester transfer protein inhibitor claims,description 20 0.000
evaporation claims,description 19 0.000
quinoxaline-2-carboxylic acid claims,description 19 0.000
solid claims,description 19 0.000
dissolution claims,description 18 0.000
Acetate claims,description 15 0.000
cellulose acetate claims,description 15 0.000
inhibitor claims,description 15 0.000
Hydroxypropyl cellulose claims,description 14 0.000
dispersion claims,description 14 0.000
hydroxypropyl cellulose claims,description 14 0.000
hydroxypropyl cellulose claims,description 14 0.000
hydrophobic effect claims,description 13 0.000
suspension claims,description 13 0.000
evaporation claims,description 9 0.000
hydroxypropyl methyl cellulose claims,description 9 0.000
hydroxypropyl methyl cellulose claims,description 9 0.000
hydroxypropyl methyl cellulose claims,description 9 0.000
melting claims,description 9 0.000
melting claims,description 9 0.000
acetic acid;butanedioic acid claims,description 8 0.000
acetic acid;phthalic acid claims,description 8 0.000
methyl cellulose claims,description 8 0.000
methylcellulose claims,description 8 0.000
methylcellulose claims,description 8 0.000
amides claims,description 7 0.000
amines claims,description 7 0.000
C-C chemokine receptor type 1 claims,description 6 0.000
C-C chemokine receptor type 1 claims,description 6 0.000
Ethyl cellulose claims,description 6 0.000
carboxylic acid derivatives claims,description 6 0.000
cellulose propionate claims,description 6 0.000
ethyl cellulose claims,description 6 0.000
ethyl cellulose claims,description 6 0.000
stirring claims,description 6 0.000
Cellulose propionate claims,description 5 0.000
methylcellulose claims,description 5 0.000
polyvinyl alcohol claims,description 5 0.000
polyvinylpyrrolidone claims,description 5 0.000
polyvinylpyrrolidone claims,description 5 0.000
polyvinylpyrrolidone claims,description 5 0.000
succinate(2-) claims,description 5 0.000
trimellitate group claims,description 5 0.000
Ethyl cellulose claims,description 4 0.000
Polyethylene claims,description 4 0.000
cooling claims,description 4 0.000
indomethacin claims,description 4 0.000
polyacrylate claims,description 4 0.000
polyethylene claims,description 4 0.000
polyvinyl alcohol claims,description 4 0.000
slurry claims,description 4 0.000
vinyl polymer claims,description 4 0.000
Cellulose acetate phthalate claims,description 3 0.000
Polyvinyl alcohol claims,description 3 0.000
cellulose acetate phthalate claims,description 3 0.000
polymethacrylate claims,description 3 0.000
1-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-3h-indol-2-one claims,description 2 0.000
Carboxymethyl cellulose claims,description 2 0.000
acetic acid;benzene-1,3-dicarboxylic acid claims,description 2 0.000
acetic acid;butanedioic acid;phthalic acid claims,description 2 0.000
acetic acid;pyridine-2,3-dicarboxylic acid claims,description 2 0.000
acetic acid;terephthalic acid claims,description 2 0.000
block copolymer claims,description 2 0.000
butanedioic acid;butanoic acid claims,description 2 0.000
butanoic acid;phthalic acid claims,description 2 0.000
carboxy methyl cellulose claims,description 2 0.000
carboxy methyl cellulose claims,description 2 0.000
carboxymethyl-cellulose claims,description 2 0.000
cellulose butyrate claims,description 2 0.000
glass transition claims,description 2 0.000
hydroxypropyl methylcellulose phthalate claims,description 2 0.000
hydroxypropyl methylcellulose phthalate claims,description 2 0.000
indomethacin claims,description 2 0.000
polyoxyethylene-polyoxypropylene claims,description 2 0.000
polypropylene glycol claims,description 2 0.000
polyvinyl acetate claims,description 2 0.000
polyvinyl acetate claims,description 2 0.000
propan-2-yl 4-[acetyl-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate claims,description 2 0.000
vinyl copolymer claims,description 2 0.000
hydroxypropyl methyl cellulose claims 3 0.000
hydroxymethyl cellulose claims 2 0.000
hydroxymethyl cellulose claims 2 0.000
Polyethylene glycol claims 1 0.000
Starch claims 1 0.000
hydroxymethylmercury claims 1 0.000
hydroxypropylcellulose claims 1 0.000
irrigation claims 1 0.000
irrigation claims 1 0.000
n-[5-(4,4-difluoro-1-hydroxycyclohexyl)-3-hydroxy-6-(hydroxyamino)-6-oxo-1-phenylhexan-2-yl]quinoxaline-2-carboxamide claims 1 0.000
phthalate(2-) claims 1 0.000
polyethylene glycol claims 1 0.000
proteins and genes claims 1 0.000
proteins and genes claims 1 0.000
quinoxaline-2-carboxamide claims 1 0.000
starch claims 1 0.000
starch claims 1 0.000
trifluoromethyl benzyl group claims 1 0.000
Show all concepts from the description section
Data provided by IFI CLAIMS Patent Services